Replies to post #108178 on Biotech Values

[biomaven0]

How much MNTA would need to be owned to make up for that loss in TEVA value?

My point exactly. I could quarrel a bit with your numbers - I don't think anywhere near half the effect is already in Teva's price at all, but that only cements the point.

On the other hand, my overall point is a bit weird, because approval of generic cop is a negative sum game for the combined companies. So owning both as a defense does on the surface seem a little strange. So maybe it reflects a currently imperfect market. I have to actually run some numbers to make better sense of it.

Peter

[DewDiligence]

The US Copaxone market accounts for more than 20% of Teva’s company-wide profits. The exact number is not disclosed, but it’s much closer to 30% than 20%, IMO. Note that Teva no longer pays SNY a 25% cut for co-marketing.